Domenico (Dinko) Valerio is a scientist and entrepreneur who founded and successfully built the biomedical company Crucell N.V., a NASDAQ, Euronext and SWX listed company. He was CEO of Crucell N.V. since its foundation in 1993 until 2004. In 1999 he also founded Galapagos Genomics N.V. as a spin-out of Crucell N.V. Galapagos Genomics N.V. went public on the Euronext stock market in 2005. In 2005 Michiel de Haan and Dinko created Aescap Venture.
Dinko has held a professorship in Gene Therapy at the Leiden University since 1992. In 1985 Dinko was a â€˜visiting scientific specialistâ€™ at Genentech Inc., San Francisco, USA. He was a post-doctoral fellow at the Salk Institute, San Diego, USA from 1986 to 1987.
He received his Master of Science degree in Biology from The University of Amsterdam and completed his Ph.D. in Molecular Genetics with Honours at Leiden University in 1986. He published over 100 scientific articles and is an inventor on 80 patents (issued from 11 patent-families).
Dinko serves on the supervisory boards of Affectis Pharmaceuticals AG, Actogenix NV and Vivendy Therapeutics Ltd.